Loading...
•
Mar 31, 2025
Iovance Q1 2025 Earnings Report
Iovance Biotherapeutics reported its first quarter 2025 financial results, including total product revenue of $49.3 million and a net loss of $116.2 million.
Key Takeaways
Iovance Biotherapeutics reported total product revenue of $49.3 million for the first quarter of 2025, primarily driven by Amtagvi sales. The company experienced a net loss of $116.2 million, or $0.36 per share. The revenue was impacted by a reduction in capacity due to scheduled maintenance at their manufacturing facility, but full production has resumed.
Total product revenue for Q1 2025 was $49.3 million, a significant increase from $0.7 million in Q1 2024, primarily due to the U.S. launch of Amtagvi.
Amtagvi sales contributed $43.6 million, while Proleukin sales accounted for $5.7 million.
The company reported a net loss of $116.2 million, or $0.36 per share, compared to a net loss of $113.0 million, or $0.42 per share in Q1 2024.
Operating expenses totaled $170.5 million, with cost of sales at $49.7 million, research and development at $76.9 million, and selling, general and administrative at $43.9 million.
Revenue by Segment
Forward Guidance
Iovance Biotherapeutics has revised its full-year 2025 total product revenue guidance to $250 million to $300 million, reflecting recent launch dynamics. The company expects significant growth in total product revenue for full year 2026 and beyond, with gross margins expected to surpass 70% over the next several years. Cash position is expected to fund operations into the second half of 2026.
Positive Outlook
- Revised full-year 2025 total product revenue guidance of $250M-$300M.
- Anticipates infusing between 100 and 110 commercial patients in Q2 2025.
- Expects significant growth in total product revenue for full year 2026 and beyond.
- Gross margins are expected to increase over time and remain on track to surpass 70% over the next several years.
- Cash position of approximately $366 million is expected to be sufficient to fund operations into the second half of 2026.
Challenges Ahead
- First quarter revenue was impacted by a significant reduction in capacity during annual scheduled maintenance at the iCTC.
- Cash burn for full year 2025 is expected to remain in line with prior guidance of less than $300 million.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...